No abstract

No abstract

No abstract

Breast cancer screening has evolved substantially over the past few decades because of advancements in new image acquisition systems and novel artificial intelligence (AI) algorithms. This review provides a brief overview of the history, current state, and future of AI in breast cancer screening and diagnosis along with challenges involved in the development of AI systems. Although AI has been developing for interpretation tasks associated with breast cancer screening for decades, its potential to combat the subjective nature and improve the efficiency of human image interpretation is always expanding. The rapid advancement of computational power and deep learning has increased greatly in AI research, with promising performance in detection and classification tasks across imaging modalities. Most AI systems, based on human-engineered or deep learning methods, serve as concurrent or secondary readers, that is, as aids to radiologists for a specific, well-defined task. In the future, AI may be able to perform multiple integrated tasks, making decisions at the level of or surpassing the ability of humans. Artificial intelligence may also serve as a partial primary reader to streamline ancillary tasks, triaging cases or ruling out obvious normal cases. However, before AI is used as an independent, autonomous reader, various challenges need to be addressed, including explainability and interpretability, in addition to repeatability and generalizability, to ensure that AI will provide a significant clinical benefit to breast cancer screening across all populations.

The Medical Imaging and Data Resource Center (MIDRC) open data commons was launched to accelerate the development of artificial intelligence (AI) algorithms to help address the COVID-19 pandemic. The purpose of this study was to quantify longitudinal representativeness of the demographic characteristics of the primary MIDRC dataset compared to the United States general population (US Census) and COVID-19 positive case counts from the Centers for Disease Control and Prevention (CDC).Approach: The Jensen-Shannon distance (JSD), a measure of similarity of two distributions, was used to longitudinally measure the representativeness of the distribution of (1) all unique patients in the MIDRC data to the 2020 US Census and (2) all unique COVID-19 positive patients in the MIDRC data to the case counts reported by the CDC. The distributions were evaluated in the demographic categories of age at index, sex, race, ethnicity, and the combination of race and ethnicity.Results: Representativeness of the MIDRC data by ethnicity and the combination of race and ethnicity was impacted by the percentage of CDC case counts for which this was not reported. The distributions by sex and race have retained their level of representativeness over time. Conclusion:The representativeness of the open medical imaging datasets in the curated public data commons at MIDRC has evolved over time as the number of contributing institutions and overall number of subjects have grown. The use of metrics, such as the JSD support measurement of representativeness, is one step needed for fair and generalizable AI algorithm development.